Despite safety concerns, Actemra usage increases among TNF-refractory patients who have failed one or two biologics
Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA), and its use is increasing despite some safety concerns, according to a new report from BioTrends. This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
At three months post-launch, compared to the prior wave at one month post-launch, a higher proportion of rheumatologists have tried Actemra and the number of RA patients who received the drug per prescriber has almost doubled.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze